<https://nucleusbiotech.com/produkt/sars-cov-2-s-b1-351-20h-501y-v2-beta-variant-s-protein-pseudotyped-luc-lentivirus-2ml/#product>
<http://schema.org/description>
"Since SARS and MERS coronaviruses are pathogenic, research on them requires bio-safety level-3 procedures which can be difficult to carry out in most commercial and university laboratories. An alternative approach is to pseudotype lentiviral particles with the coronavirus coat proteins. This enables researchers to carry out studies on these viral elements in S2 laboratories.\nWe offer third-generation replication-incompetent lentiviral vectors expressing the luciferase reporter gene, packaged as viral particles which are pseudotyped with the SARS COV-2 Beta, V2 B.1.351 Variant Spike-Protein 20H/501Y.V2 , which shows enhanced recognition and binding to the ACE2 cell surface receptor to mediate coronavirus cell entry.  The particles were functionally tested by Luciferase assay performance (signal increase of at least 10-fold above background) in Cellecta HeLa-ACE2 Overexpression Cells.\nThis product enables investigators to run neutralization assays and related studies that investigate factors which influence 20H/501Y.V2 spike protein recognition and binding to target cells in S2 laboratories.\n\nContents:  2ml SARS-CoV-2 Beta Variant S-protein pseudotyped lentiviral particles, functionally tested by Luciferase assays in HeLa-ACE2 overexpression cells.\n\nNumber of Reactions:  40 rxns when using 50 ul reagent per well in a 96-well plate"
<https://nucleusbiotech.com/produkt/sars-cov-2-s-b1-351-20h-501y-v2-beta-variant-s-protein-pseudotyped-luc-lentivirus-2ml/>